Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 3/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.43 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.43 |
| ▸ | GABRP | O00591 | 1/20 | 0.43 |
| ▸ | GABRD | O14764 | 1/20 | 0.43 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.43 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.43 |
| ▸ | GABRE | P78334 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.43 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.43 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.43 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.43 |
| ▸ | SLC6A1 | P30531 | 4/20 | 0.42 |
| ▸ | SLC6A11 | P48066 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2148728 | 1.00 | GABRA5 (0.43) | GABRA5GABRB2TSHRGABRA1GABRA4 | |
| SCHEMBL2672481 | 1.00 | GABRA5 (0.43) | GABRA5GABRB2TSHRGABRA1GABRA4 | |
| Hydrochloric Acid SCHEMBL2146778 | 0.98 | GABRA5 (0.41) | GABRA5GABRB2TSHRGABRA1GABRA4 | |
| Hydrochloric Acid SCHEMBL1464969 | 0.98 | GABRA5 (0.41) | GABRA5GABRB2TSHRGABRA1GABRA4 | |
| Hydrochloric Acid SCHEMBL2146165 | 0.98 | GABRA5 (0.41) | GABRA5GABRB2TSHRGABRA1GABRA4 | |
| SCHEMBL716055 | 0.88 | SLC6A1 (0.59) | TSHRSLC6A1SLC6A11SLC6A13LMNA | |
| SCHEMBL6791489 | 0.88 | SLC6A1 (0.59) | TSHRSLC6A1SLC6A11SLC6A13LMNA | |
| SCHEMBL16584230 | 0.88 | SLC6A1 (0.59) | TSHRSLC6A1SLC6A11SLC6A13LMNA | |
| Trifluoroacetic Acid SCHEMBL3008464 | 0.88 | GABRA5 (0.38) | GABRA5GABRB2TSHRGABRA1GABRA4 | |
| Trifluoroacetic Acid SCHEMBL3006379 | 0.88 | GABRA5 (0.38) | GABRA5GABRB2TSHRGABRA1GABRA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116583283-A | CDK inhibitors and their use as pharmaceuticals | 普莱鲁德疗法有限公司 | 2023-08-11 | — | — | CN | claimed |
| CN-115611924-A | PD-1/PD-L1 inhibitor and preparation method and application thereof | 上海华汇拓医药科技有限公司 | 2023-01-17 | — | — | CN | claimed |
| CN-109311860-B | Xanthone derivatives for the treatment or prevention of hepatitis B virus diseases | 豪夫迈·罗氏有限公司 | 2022-04-08 | — | — | CN | claimed |
| US-12454547-B2 | Steroidal compositions and methods of treating lipogenic cancers | Asteroid Therapeutics (US) | 2025-10-28 | — | — | US | disclosed |
| US-12441691-B2 | Bicyclic 1,4-diazepanones and therapeutic uses thereof | CYTOKINETICS, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-20240368091-A1 | BICYCLIC 1,4-DIAZEPANONES AND THERAPEUTIC USES THEREOF | CYTOKINETICS, INC. | 2024-11-07 | — | — | US | disclosed |
| EP-4419527-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | Artios Pharma Limited (GB) | 2024-08-28 | — | — | EP | disclosed |
| CN-118339156-A | 2-Diazo-3-oxo-2, 3-dihydrospiro [ indene-1, 9' -xanthene ] derivatives and similar compounds as photoactive fluorescent compounds for protein labelling | 爱康治疗公司 | 2024-07-12 | — | — | CN | disclosed |
| US-11981644-B2 | Bicyclic 1,4-diazepanones and therapeutic uses thereof | CYTOKINETICS, INC. (US) | 2024-05-14 | — | — | US | disclosed |
| CN-111417635-B | Pyrazolopyrimidines with anti-Respiratory Syncytial Virus (RSV) activity | 爱尔兰詹森科学公司 | 2024-01-02 | — | — | CN | disclosed |
| WO-2023205801-A2 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics (US) | 2023-10-26 | — | — | WO | disclosed |
| US-20080064682-A1 | Pyrazole Derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-03-13 | — | — | US | disclosed |
| US-20070254881-A1 | Pyrazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-11-01 | — | — | US | disclosed |
| EP-1803719-A1 | 1,5-DIHETEROCYCLE-1H-TRIAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-07-04 | — | — | EP | disclosed |
| EP-1785418-A1 | PYRAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-05-16 | — | — | EP | disclosed |
| EP-1762568-A1 | PYRAZOLE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-14 | — | — | EP | disclosed |
| US-20060189591-A1 | Five-membered heterocyclic derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-08-24 | — | — | US | disclosed |
| US-20060128685-A1 | Pyrazole derivative | DAIICHI PHARMACEUTICAL CO., LTD., (JP) | 2006-06-15 | — | — | US | disclosed |
| EP-1621537-A1 | FIVE-MEMBERED HETEROCYCLIC DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-02-01 | — | — | EP | disclosed |
| EP-1591443-A1 | PYRAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12454547-B2 | Steroidal compositions and methods of treating lipogenic cancers | SREBF1, SREBF2, NR1H3 | GABRA5 3007/4885GABRB2 2007/4885TSHR 2363/4885 |
| US-20070254881-A1 | Pyrazole Derivative | PTGER1, PTGS1, PTGER2 | GABRA5 2076/4885GABRB2 2102/4885TSHR 4178/4885 |
| US-20060128685-A1 | Pyrazole derivative | PTGS1, PTGS2, PTGER1 | GABRA5 2263/4885GABRB2 2357/4885TSHR 4631/4885 |
| US-20240368091-A1 | BICYCLIC 1,4-DIAZEPANONES AND THERAPEUTIC USES THEREOF | MYLK2, MUSK, MYLK | GABRA5 1002/4885GABRB2 483/4885TSHR 2030/4885 |
| US-20080064682-A1 | Pyrazole Derivatives | NAT1, AR, CBR3 | GABRA5 1555/4885GABRB2 1970/4885TSHR 2789/4885 |
| US-20060189591-A1 | Five-membered heterocyclic derivative | PTGS1, PTGIS, PTGS2 | GABRA5 1691/4885GABRB2 3006/4885TSHR 4671/4885 |
| US-12441691-B2 | Bicyclic 1,4-diazepanones and therapeutic uses thereof | MYLK2, MUSK, MYLK | GABRA5 1002/4885GABRB2 483/4885TSHR 2030/4885 |
| US-11981644-B2 | Bicyclic 1,4-diazepanones and therapeutic uses thereof | MYLK2, MUSK, MYLK | GABRA5 1053/4885GABRB2 498/4885TSHR 2067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.